These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 2445297)

  • 21. Antipsoriatic and proinflammatory action of anthralin. Implications for the role of oxygen radicals.
    Müller K
    Biochem Pharmacol; 1997 May; 53(9):1215-21. PubMed ID: 9214681
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current concepts in the mode of action of anthralin in the treatment of psoriasis.
    Br J Dermatol; 1981 Aug; 105 Suppl 20():1-114. PubMed ID: 7284252
    [No Abstract]   [Full Text] [Related]  

  • 23. Free radical reduction by thioredoxin reductase at the surface of normal and vitiliginous human keratinocytes.
    Schallreuter KU; Pittelkow MR; Wood JM
    J Invest Dermatol; 1986 Dec; 87(6):728-32. PubMed ID: 2431070
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Modified dithranol minute therapy of psoriasis vulgaris].
    Chlebarov S; Rauh M
    Z Hautkr; 1988 Aug; 63(8):658-62. PubMed ID: 3188606
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Short-contact anthralin treatment augments therapeutic efficacy of cyclosporine in psoriasis: a clinical and pathologic study.
    Gottlieb SL; Heftler NS; Gilleaudeau P; Johnson R; Vallat VP; Wolfe J; Gottlieb AB; Krueger JG
    J Am Acad Dermatol; 1995 Oct; 33(4):637-45. PubMed ID: 7545705
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A stable mixed disulfide between thioredoxin reductase and its substrate, thioredoxin: preparation and characterization.
    Wang PF; Veine DM; Ahn SH; Williams CH
    Biochemistry; 1996 Apr; 35(15):4812-9. PubMed ID: 8664271
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anthralin (dithranol) in vitro inhibits human monocytes to secrete IL-6, IL-8 and TNF-alpha, but not IL-1.
    Mrowietz U; Jessat H; Schwarz A; Schwarz T
    Br J Dermatol; 1997 Apr; 136(4):542-7. PubMed ID: 9155955
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-psoriatic drug anthralin activates transcription factor NF-kappa B in murine keratinocytes.
    Schmidt KN; Podda M; Packer L; Baeuerle PA
    J Immunol; 1996 Jun; 156(11):4514-9. PubMed ID: 8666828
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanisms of the regulation of thioredoxin reductase activity in cancer cells by the chemopreventive agent selenium.
    Gallegos A; Berggren M; Gasdaska JR; Powis G
    Cancer Res; 1997 Nov; 57(21):4965-70. PubMed ID: 9354464
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of thioredoxin reductase in the reduction of free radicals at the surface of the epidermis.
    Schallreuter KU; Wood JM
    Biochem Biophys Res Commun; 1986 Apr; 136(2):630-7. PubMed ID: 2423087
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The stereospecific suicide inhibition of human melanoma thioredoxin reductase by 13-cis-retinoic acid.
    Schallreuter KU; Wood JM
    Biochem Biophys Res Commun; 1989 Apr; 160(2):573-9. PubMed ID: 2719682
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of dithranol on neutrophil superoxide generation in patients with psoriasis.
    Kavanagh GM; Burton JL; Donnell VO
    Br J Dermatol; 1996 Feb; 134(2):234-7. PubMed ID: 8746335
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mast cell alterations in chronic psoriasis vulgaris: response to low-strength anthralin treatment. A transmission electron microscopic study.
    Brody I
    Ups J Med Sci; 1986; 91(1):1-16. PubMed ID: 3716018
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Combined 1-hour therapy of psoriasis using anthralin and UV light].
    Schauder S; Mahrle G
    Hautarzt; 1982 Apr; 33(4):206-9. PubMed ID: 7096083
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasminogen activation in psoriasis.
    Lotti T; Bonan P; Panconesi E
    Acta Derm Venereol Suppl (Stockh); 1989; 146():36-8. PubMed ID: 2514542
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Disappearance of psoriactic lesions under the effect of anthralin].
    Chowaniec O
    Przegl Dermatol; 1976; 63(5):665-71. PubMed ID: 1005760
    [No Abstract]   [Full Text] [Related]  

  • 37. [Effect of the treatment of psoriasis with dithranol in comparison with a combination of dithranol and a corticosteroid].
    Gloor M; Graf R; Wirth H; Landau M
    Hautarzt; 1983 Oct; 34(10):500-3. PubMed ID: 6643055
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The irritancy of anthralin is inhibited by repeat applications of a subirritant concentration.
    Parslew R; Friedmann PS
    Br J Dermatol; 1999 Sep; 141(3):469-74. PubMed ID: 10583050
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Study on the mode of action of dithranol: increased lipid peroxidation and enzyme inhibition].
    Diezel W; Meffert H; Sönnichsen N
    Dermatologica; 1975; 150(3):154-62. PubMed ID: 125665
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Old wine in new bottles: the revival of anthralin.
    Harris DR
    Cutis; 1998 Oct; 62(4):201-3. PubMed ID: 9798112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.